{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:26:22Z","timestamp":1783445182679,"version":"3.54.6"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Although biomarkers are useful diagnostic tools to assess joint damage in osteoarthritis and rheumatoid arthritis, few data exist for biomarkers of haemophilic arthropathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the association between biomarkers and compatible additive magnetic resonance imaging (<jats:styled-content style=\"fixed-case\">MRI<\/jats:styled-content>) scores in patients with severe haemophilia A.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients aged 12\u201335 years with no history of factor <jats:styled-content style=\"fixed-case\">VIII<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content>) inhibitors were enrolled in a controlled, cross\u2010sectional, multinational investigation. Patients received primary or secondary prophylaxis or on\u2010demand treatment with <jats:styled-content style=\"fixed-case\">FVIII<\/jats:styled-content> and underwent <jats:styled-content style=\"fixed-case\">MRI<\/jats:styled-content> on four joints (two ankles, two knees). Soluble biomarkers of cartilage and bone degradation, inflammation, and angiogenesis were assessed (serum levels of C\u2010terminal telopeptides of type I collagen [<jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content>\u2010I], cartilage oligomeric matrix protein [<jats:styled-content style=\"fixed-case\">COMP<\/jats:styled-content>], chondroitin\u2010sulphate aggrecan turnover 846 epitope [<jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content>846], tissue inhibitor of metalloproteinase 1 [<jats:styled-content style=\"fixed-case\">TIMP<\/jats:styled-content>\u20101]; plasma levels of vascular endothelial growth factor [<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content>], matrix metalloproteinases 3 and 9 [<jats:styled-content style=\"fixed-case\">MMP<\/jats:styled-content>3, <jats:styled-content style=\"fixed-case\">MMP<\/jats:styled-content>9]). Relationships between biomarkers and <jats:styled-content style=\"fixed-case\">MRI<\/jats:styled-content> scores were evaluated using Spearman rank correlation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Biomarkers were assessed in 117 of 118 per\u2010protocol patients. Mean and median <jats:styled-content style=\"fixed-case\">CTX<\/jats:styled-content>\u2010I, <jats:styled-content style=\"fixed-case\">COMP<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> TIMP<\/jats:styled-content>\u20101, <jats:styled-content style=\"fixed-case\">MMP<\/jats:styled-content>3, <jats:styled-content style=\"fixed-case\">MMP<\/jats:styled-content>9, and <jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> values were within normal ranges (reference range not available for <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content>846 in healthy volunteers). No correlations between biomarkers and <jats:styled-content style=\"fixed-case\">MRI<\/jats:styled-content> scores were found, with the exception of <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content>846, which showed significant correlation in a subgroup of 22 on\u2010demand patients (<jats:italic>r<\/jats:italic> = 0.436; <jats:italic>P<\/jats:italic> = 0.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compatible additive <jats:styled-content style=\"fixed-case\">MRI<\/jats:styled-content> scores showed no clear correlations with any of the potential biomarkers for haemophilic arthropathy in the overall population. <jats:styled-content style=\"fixed-case\">CS<\/jats:styled-content>846 levels were significantly correlated with <jats:styled-content style=\"fixed-case\">MRI<\/jats:styled-content> scores in patients treated on demand.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.12936","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T11:20:49Z","timestamp":1466767249000},"page":"760-764","source":"Crossref","is-referenced-by-count":26,"title":["Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores"],"prefix":"10.1111","volume":"22","author":[{"given":"J.","family":"Oldenburg","sequence":"first","affiliation":[{"name":"University Clinic Bonn Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Kurpfalz Hospital and Haemophilia Centre for Children and Adults Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Katsarou","sequence":"additional","affiliation":[{"name":"Laikon General Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zanon","sequence":"additional","affiliation":[{"name":"University of Padua Medical School Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kellermann","sequence":"additional","affiliation":[{"name":"Bayer Vital GmbH Leverkusen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lundin","sequence":"additional","affiliation":[{"name":"Lund University and Sk\u00e5ne University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ellinghaus","sequence":"additional","affiliation":[{"name":"Bayer Pharma AG Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365513.2010.493406"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3280"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328349a32b"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200309000-00020"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24184"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_7_9_1","first-page":"251","article-title":"Long\u2010term therapy and on\u2010demand treatment of children and adolescents with severe haemophilia A: 12 years of experience","volume":"22","author":"Brackmann HH","year":"1992","journal-title":"Haemostasis"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12202"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03962.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01049.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12539"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.01927.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21977"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1037-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000131"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.12.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-284653"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2014.09.008"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02109.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02044.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00433.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02496.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12936","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.12936","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T23:27:15Z","timestamp":1694906835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/hae.12936"],"URL":"https:\/\/doi.org\/10.1111\/hae.12936","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,24]]}}}